Dietary supplements and human health: For better or for worse?

Molecular Nutrition and Food Research

Volumn 55, Issue 1, 2011, Pages 122-135

  Jerome Morais, Anita ^a   Diamond, Alan M ^a   Wright, Margaret E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Carotene; Antioxidant; Genistein; Selenium; Supplements

Indexed keywords

ANTIOXIDANT; BETA CAROTENE; GENISTEIN; SELENIUM;

ANIMAL; ARTICLE; CHEMOPROPHYLAXIS; CHRONIC DISEASE; DIET SUPPLEMENTATION; FEEDING BEHAVIOR; HEALTH; HUMAN; LIFESTYLE; META ANALYSIS (TOPIC); NUTRITION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTIOXIDANTS; BETA CAROTENE; CHEMOPREVENTION; CHRONIC DISEASE; DIETARY SUPPLEMENTS; FOOD HABITS; GENISTEIN; HEALTH; HUMANS; LIFE STYLE; META-ANALYSIS AS TOPIC; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELENIUM;

ANIMALIA;

EID: 78650889036     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000415     Document Type: Article

References (156)

1. Fletcher, W., Rice and Beri-Beri: preliminary report on an experiment conducted at the Kuala Lampur lunatic asylum. Lancet 1907, 169, 1776-1779.
2. Lind, J., Nutrition classics. A treatise of the scurvy by James Lind, MDCCLIII. Nutr. Rev. 1983, 41, 155-157.
3. Wolf, G., A historical note on the mode of administration of vitamin A for the cure of night blindness. Am. J. Clin. Nutr. 1978, 31, 290-292.
4. Shils, M. E., Shike, M., Ross, A. C., Caballero, B., Cousins, R. J. (Eds.), Modern Nutrition in Health and Disease, Lippincott Williams & Wilkins, Baltimore, MD 2006.
5. Klenner, F. R., The treatment of poliomyelitis and other virus diseases with vitamin C. South Med. Surg. 1949, 111, 209-214.
6. Yu, B. P., Cellular defenses against damage from reactive oxygen species. Physiol. Rev. 1994, 74, 139-162.
7. Castro, L., Freeman, B. A., Reactive oxygen species in human health and disease. Nutrition 2001, 17, 161, 163-165.
8. Millen, A. E., Dodd, K. W., Subar, A. F., Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. J. Am. Diet Assoc. 2004, 104, 942-950.
9. 2009 Supplement Business Report, Nutr. Bus. J., New Hope Natural Media, P. M. I. (Ed.), San Diego, CA 2009.
10. Blendon, R. J., DesRoches, C. M., Benson, J. M., Brodie, M., Altman, D. E., Americans' views on the use and regulation of dietary supplements. Arch. Intern. Med. 2001, 161, 805-810.
11. Albanes, D., Beta-carotene and lung cancer: a case study. Am. J. Clin. Nutr. 1999, 69, 1345S-1350S.
12. Mayne, S. T., Beta-carotene, carotenoids, and disease prevention in humans. FASEB J. 1996, 10, 690-701.
13. Omenn, G. S., Chemoprevention of lung cancer: the rise and demise of beta-carotene. Annu. Rev. Public Health 1998, 19, 73-99.
14. Rock, C. L., Carotenoids: biology and treatment. Pharmacol. Ther. 1997, 75, 185-197.
15. Peto, R., Doll, R., Buckley, J. D., Sporn, M. B., Can dietary beta-carotene materially reduce human cancer rates? Nature 1981, 290, 201-208.
16. IARC Working Group on the Evaluation of Cancer-preventive Agents, World Health Organization, International Agency for Research on Cancer, IARC Handbooks of Cancer Prevention, Volume 2: Carotenoids, Oxford University Press, Lyon, France and Carey, N. C. 1998.
17. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029-1035.
18. Albanes, D., Heinonen, O. P., Taylor, P. R., Virtamo, J. et al., Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J. Natl. Cancer Inst. 1996, 88, 1560-1570.
19. Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J. et al., Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1150-1155.
20. Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J. et al., Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J. Natl. Cancer Inst. 1996, 88, 1550-1559.
21. Hennekens, C. H., Buring, J. E., Manson, J. E., Stampfer, M. et al., Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1145-1149.
22. Cook, N. R., Le, I. M., Manson, J. E., Buring, J. E., Hennekens, C. H., Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Control 2000, 11, 617-626.
23. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360, 23-33.
24. Kamangar, F., Qiao, Y. L., Yu, B., Sun, X. D. et al., Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1562-1564.
25. Lee, I. M., Cook, N. R., Manson, J. E., Buring, J. E., Hennekens, C. H., Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J. Natl. Cancer Inst. 1999, 91, 2102-2106.
26. Lin, J., Cook, N. R., Albert, C., Zaharris, E. et al., Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J. Natl. Cancer Inst. 2009, 101, 14-23.
27. Liu, C., Russell, R. M., Wang, X. D., Exposing ferrets to cigarette smoke and a pharmacological dose of beta-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J. Nutr. 2003, 133, 173-179.
28. Liu, C., Wang, X. D., Bronson, R. T., Smith, D. E. et al., Effects of physiological versus pharmacological beta-carotene supplementation on cell proliferation and histopathological changes in the lungs of cigarette smoke-exposed ferrets. Carcinogenesis 2000, 21, 2245-2253.
29. Wang, X. D., Liu, C., Bronson, R. T., Smith, D. E. et al., Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J. Natl. Cancer Inst. 1999, 91, 60-66.
30. Wright, M. E., Groshong, S. D., Husgafvel-Pursiainen, K., Genova, E. et al., Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. Cancer Prev. Res. (Phila Pa) 2010, 3, 745-752.
31. Liu, C., Wang, X. D., Mucci, L., Gaziano, J. M., Zhang, S. M., Modulation of lung molecular biomarkers by beta-carotene in the Physicians' Health Study. Cancer 2009, 115, 1049-1058.
32. Mayne, S. T., Beta-carotene, carotenoids, and cancer prevention. PPO Updates 1998, 12, 1-15.
33. Dallongeville, J., Marecaux, N., Fruchart, J. C., Amouyel, P., Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J. Nutr. 1998, 128, 1450-1457.
34. World Cancer Research Fund, American Institute for Cancer Research, Food, nutrition, physical activity, and the prevention of cancer: a global perspective, Washington, DC 2007.
35. Touvier, M., Kesse, E., Clavel-Chapelon, F., Boutron-Ruault, M. C., Dual Association of beta-carotene with risk of tobacco-related cancers in a cohort of French women. J. Natl. Cancer Inst. 2005, 97, 1338-1344.
36. Schwarz, K., Foltz, C. M., Factor 3 activity of selenium compounds. J. Biol. Chem. 1958, 233, 245-251.
37. Tan, J., Zhu, W., Wang, W., Li, R. et al., Selenium in soil and endemic diseases in China. Sci. Total Environ. 2002, 284, 227-235.
38. Zimmerman, M., Kohrle, J., The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid 2002, 12, 867-878.
39. Li, Y., Peng, T., Yang, Y., Niu, C. et al., High prevalence of enteroviral genomic sequences in myocardium from cases of endemic cardiomyopathy (Keshan disease) in China. Heart 2000, 83, 696-701.
40. Lei, C., Niu, X., Wei, J., Zhu, J., Zhu, Y., Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy. Clin. Chim. Acta 2009, 399, 102-108.
41. Rayman, M. P., The importance of selenium to human health. Lancet 2000, 356, 233-241.
42. Papp, L. V., Lu, J., Holmgren, A., Khanna, K. K., From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signal. 2007, 9, 775-806.
43. Jung, H. J., Seo, Y. R., Current issues of selenium in cancer chemoprevention. Biofactors 2010, 36, 153-158.
44. El-Bayoumy, K. (Ed.), The Role of Selenium in Cancer Prevention, J. B. Lippincott Co., Philadelphia 1991.
45. Gromadzinska, J., Reszka, E., Bruzelius, K., Wasowicz, W., Akesson, B., Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur. J. Nutr. 2008, 47, 29-50.
46. Peters, U., Takata, Y., Selenium and the prevention of prostate and colorectal cancer. Mol. Nutr. Food Res. 2008, 52, 1261-1272.
47. Yang, G., Wang, S., Zhou, R., Sun, S., Endemic selenium intoxication of humans in China. Am. J. Clin. Nutr. 1983, 37, 872-881.
48. Nuttall, K. L., Evaluating selenium poisoning. Ann. Clin. Lab Sci. 2006, 36, 409-420.
49. MacFarquhar, J. K., Broussard, D. L., Melstrom, P., Hutchinson, R. et al., Acute selenium toxicity associated with a dietary supplement. Arch. Intern. Med. 2010, 170, 256-261.
50. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, A Report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, National Academy Press, Washington, DC 2000.
51. Valdiglesias, V., Pasaro, E., Mendez, J., Laffon, B., In vitro evaluation of selenium genotoxic, cytotoxic, and protective effects: a review. Arch. Toxicol. 2009, 84, 337-351.
52. Clark, L. C., Combs, G. F. J., Turnbull, B. W., Slate, E. H. et al., Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. J. Am. Med. Assoc. 1996, 276, 1957-1963.
53. Duffield-Lillicoe, A., Reid, M., Turnbull, J., Combs, G. J. et al., Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 630-639.
54. Duffield-Lillico, A. J., Dalkin, B. L., Reid, M. E., Turnbull, B. W. et al., Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. Br. J. Urol. Int. 2003, 91, 608-612.
55. Stranges, S., Marshall, J. R., Natarajan, R., Donahue, R. P. et al., Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann. Intern. Med. 2007, 147, 217-223.
56. Lippman, S. M., Goodman, P. J., Klein, E. A., Parnes, H. L. et al., Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Natl. Cancer Inst. 2005, 97, 94-102.
57. Lippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S. et al., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Am. Med. Assoc. 2009, 301, 39-51.
58. Laclaustra, M., Navas-Acien, A., Stranges, S., Ordovas, J. M., Guallar, E., Serum selenium concentrations and diabetes in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ. Health Perspect. 2009, 117, 1409-1413.
59. Bleys, J., Navas-Acien, A., Guallar, E., Serum selenium and diabetes in US adults. Diabetes Care 2007, 30, 829-834.
60. Bleys, J., Navas-Acien, A., Laclaustra, M., Pastor-Barriuso, R. et al., Serum selenium and peripheral arterial disease: results from the national health and nutrition examination survey, 2003-2004. Am. J. Epidemiol. 2009, 169, 996-1003.
61. Stranges, S., Laclaustra, M., Ji, C., Cappuccio, F. P. et al., Higher selenium status is associated with adverse blood lipid profile in British adults. J. Nutr. 2009, 140, 81-87.
62. Bleys, J., Navas-Acien, A., Guallar, E., Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch. Intern. Med. 2008, 168, 404-410.
63. Kryukov, G. V., Castellano, S., Novoselov, S. V., Lobanov, A. V. et al., Characterization of mammalian selenoproteomes. Science 2003, 300, 1439-1443.
64. Reeves, M. A., Hoffmann, P. R., The human selenoproteome: recent insights into functions and regulation. Cell Mol. Life Sci. 2009, 66, 2457-2478.
65. Flohe, L., The labour pains of biochemical selenology: the history of selenoprotein biosynthesis. Biochim. Biophys. Acta 2009, 1790, 1389-1403.
66. Baliga, M. S., Diwadkar-Navsariwala, V., Koh, T., Fayad, R. et al., Selenoprotein deficiency enhances radiation-induced micronuclei formation. Mol. Nutr. Food Res. 2008, 52, 1300-1304.
67. Baliga, M. S., Wang, H., Zhuo, P., Schwartz, J. L., Diamond, A. M., Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage. Biol. Trace Elem. Res. 2007, 115, 227-242.
68. Weiss Sachdev, S., Sunde, R. A., Selenium regulation of transcript abundance and translational efficiency of glutathione peroxidase-1 and -4 in rat liver. Biochem. J. 2001, 357, 851-858.
69. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L., Korsmeyer, S. J., Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993, 75, 241-251.
70. McClung, J. P., Roneker, C. A., Mu, W., Lisk, D. J. et al., Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc. Natl. Acad. Sci. USA 2004, 101, 8852-8857.
71. Zhuo, P., Diamond, A. M., Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim. Biophys. Acta 2009, 790, 1546-1554.
72. Zhuo, P., Goldberg, M., Herman, L., Lee, B. S. et al., Molecular consequences of genetic variations in the glutathione peroxidase 1 selenoenzyme. Cancer Res. 2009, 69, 8183-8190.
73. Messina, M., Nagata, C., Wu, A. H., Estimated Asian adult soy protein and isoflavone intakes. Nutr. Cancer 2006, 55, 1-12.
74. Yatani, R., Chigusa, I., Akazaki, K., Stemmermann, G. N. et al., Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 1982, 29, 611-616.
75. Tham, D. M., Gardner, C. D., Haskell, W. L., Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 1998, 83, 2223-2235.
76. Ziegler, R. G., Hoover, R. N., Pike, M. C., Hildesheim, A. et al., Migration patterns and breast cancer risk in Asian-American women. J. Natl. Cancer Inst. 1993, 85, 1819-1827.
77. Lee, H. P., Gourley, L., Duffy, S. W., Esteve, J. et al., Dietary effects on breast-cancer risk in Singapore. Lancet 1991, 337, 1197-1200.
78. Trock, B. J., Hilakivi-Clarke, L., Clarke, R., Meta-analysis of soy intake and breast cancer risk. J. Natl. Cancer Inst. 2006, 98, 459-471.
79. Anderson, J. W., Johnstone, B. M., Cook-Newell, M. E., Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 1995, 333, 276-282.
80. Potter, S. M., Baum, J. A., Teng, H., Stillman, R. J. et al., Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 1998, 68, 1375S-1379S.
81. Arjmandi, B. H., Alekel, L., Hollis, B. W., Amin, D. et al., Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J. Nutr. 1996, 126, 161-167.
82. Murkies, A. L., Lombard, C., Strauss, B. J., Wilcox, G. et al., Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 2008, 61, 27-33.
83. Lethaby, A. E., Brown, J., Marjoribanks, J., Kronenberg, F. et al., Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst. Rev. (Online) 2007, CD001395.
84. Howes, L. G., Howes, J. B., Knight, D. C., Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas 2006, 55, 203-211.
85. Wu, A. H., Wan, P., Hankin, J., Tseng, C. C. et al., Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002, 23, 1491-1496.
86. Arora, A., Nair, M. G., Strasburg, G. M., Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch. Biochem. Biophys. 1998, 356, 133-141.
87. Ruiz-Larrea, M. B., Mohan, A. R., Paganga, G., Miller, N. J. et al., Antioxidant activity of phytoestrogenic isoflavones. Free Radic. Res. 1997, 26, 63-70.
88. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H. et al., Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592-5595.
89. Dahlman-Wright, K., Cavailles, V., Fuqua, S. A., Jordan, V. C. et al., International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 2006, 58, 773-781.
90. Beato, M., Sanchez-Pacheco, A., Interaction of steroid hormone receptors with the transcription initiation complex. Endocr. Rev. 1996, 17, 587-609.
91. Beekman, J. M., Allan, G. F., Tsai, S. Y., Tsai, M. J., O'Malley, B. W., Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 1993, 7, 1266-1274.
92. Taylor, C. K., Levy, R. M., Elliott, J. C., Burnett, B. P., The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr. Rev. 2009, 67, 398-415.
93. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E. et al., Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138, 863-870.
94. Kuiper, G. G., Lemmen, J. G., Carlsson, B., Corton, J. C. et al., Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139, 4252-4263.
95. Hsieh, R. W., Rajan, S. S., Sharma, S. K., Guo, Y. et al., Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J. Biol. Chem. 2006, 281, 17909-17919.
96. Sotoca, A. M., Sollewijn Gelpke, M. D., Boeren, S., Ström, A. et al., Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects on T47D breast cancer cells exposed to the phytoestrogen genistein. Mol. Cell. Proteomics 2010, in press, Doi: 10.1074/mcp.M110.002170.
97. Iwasaki, M., Inoue, M., Otani, T., Sasazuki, S. et al., Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J. Clin. Oncol. 2008, 26, 1677-1683.
98. Verheus, M., van Gils, C. H., Keinan-Boker, L., Grace, P. B. et al., Plasma phytoestrogens and subsequent breast cancer risk. J. Clin. Oncol. 2007, 25, 648-655.
99. Marini, H., Bitto, A., Altavilla, D., Burnett, B. P. et al., Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J. Clin. Endocrinol. Metab. 2008, 93, 4787-4796.
100. Ward, H., Chapelais, G., Kuhnle, G. G., Luben, R. et al., Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European prospective into cancer-norfolk cohort study. Breast Cancer Res. 2008, 10, R32.
101. Grace, P. B., Taylor, J. I., Low, Y. L., Luben, R. N. et al., Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 698-708.
102. Piller, R., Chang-Claude, J., Linseisen, J., Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur. J. Cancer Prev. 2006, 15, 225-232.
103. den Tonkelaar, I., Keinan-Boker, L., Veer, P. V., Arts, C. J. et al., Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 223-228.
104. Wei, H., Bowen, R., Zhang, X., Lebwohl, M., Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis 1998, 19, 1509-1514.
105. Upadhyaya, P., El-Bayoumy, K., Effect of dietary soy protein isolate, genistein, and 1, 4-phenylenebis(methylene)selenocyanate on DNA binding of 7, 12-dimethylbenz[a]anthracene in mammary glands of CD rats. Oncol. Rep. 1998, 5, 1541-1545.
106. Lamartiniere, C. A., Timing of exposure and mammary cancer risk. J. Mammary Gland Biol. Neoplasia 2002, 7, 67-76.
107. Lamartiniere, C. A., Moore, J. B., Brown, N. M., Thompson, R. et al., Genistein suppresses mammary cancer in rats. Carcinogenesis 1995, 16, 2833-2840.
108. Kousidou, O. C., Mitropoulou, T. N., Roussidis, A. E., Kletsas, D. et al., Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int. J. Oncol. 2005, 26, 1101-1109.
109. Wang, J., Eltoum, I. E., Carpenter, M., Lamartiniere, C. A., Genistein mechanisms and timing of prostate cancer chemoprevention in lobund-wistar rats. Asian Pac. J. Cancer Prev. 2009, 10, 143-150.
110. Rucinska, A., Roszczyk, M., Gabryelak, T., Cytotoxicity of the isoflavone genistein in NIH 3T3 cells. Cell Biol. Int. 2008, 32, 1019-1023.
111. Fioravanti, L., Cappelletti, V., Miodini, P., Ronchi, E. et al., Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett. 1998, 130, 143-152.
112. Le Bail, J. C., Varnat, F., Nicolas, J. C., Habrioux, G., Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett. 1998, 130, 209-216.
113. Li, Y., Ahmed, F., Ali, S., Philip, P. A. et al., Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65, 6934-6942.
114. Mohammad, R. M., Banerjee, S., Li, Y., Aboukameel, A. et al., Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006, 106, 1260-1268.
115. Li, Y., Ellis, K. L., Ali, S., El-Rayes, B. F. et al., Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 2004, 28, e90-e95.
116. Gong, L., Li, Y., Nedeljkovic-Kurepa, A., Sarkar, F. H., Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003, 22, 4702-4709.
117. Valachovicova, T., Slivova, V., Bergman, H., Shuherk, J., Sliva, D., Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. Int. J. Oncol. 2004, 25, 1389-1395.
118. Farina, H. G., Pomies, M., Alonso, D. F., Gomez, D. E., Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol. Rep. 2006, 16, 885-891.
119. Fan, S., Meng, Q., Auborn, K., Carter, T., Rosen, E. M., BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br. J. Cancer 2006, 94, 407-426.
120. Wei, H., Wei, L., Frenkel, K., Bowen, R., Barnes, S., Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr. Cancer 1993, 20, 1-12.
121. Choi, Y. H., Lee, W. H., Park, K. Y., Zhang, L., p53-Independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 2000, 91, 164-173.
122. Cho, K. H., Pezzuto, J. M., Bolton, J. L., Steele, V. E. et al., Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur. J. Cancer 2000, 36, 2146-2156.
123. Rimbach, G., Boesch-Saadatmandi, C., Frank, J., Fuchs, D. et al., Dietary isoflavones in the prevention of cardiovascular disease - a molecular perspective. Food Chem. Toxicol. 2008, 46, 1308-1319.
124. Williamson-Hughes, P. S., Flickinger, B. D., Messina, M. J., Empie, M. W., Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 2006, 13, 831-839.
125. Wegrzyn, G., Jakobkiewicz-Banecka, J., Gabig-Ciminska, M., Piotrowska, E. et al., Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem. Soc. Trans. 2010, 38, 695-701.
126. Boos, G., Stopper, H., Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol. Lett. 2000, 116, 7-16.
127. Kim, Y. M., Yang, S., Xu, W., Li, S., Yang, X., Continuous in vitro exposure to low-dose genistein induces genomic instability in breast epithelial cells. Cancer Genet. Cytogenet. 2008, 186, 78-84.
128. Pool-Zobel, B. L., Adlercreutz, H., Glei, M., Liegibel, U. M. et al., Isoflavonoids and lignans have different potentials to modulate oxidative genetic damage in human colon cells. Carcinogenesis 2000, 21, 1247-1252.
129. Michael McClain, R., Wolz, E., Davidovich, A., Bausch, J., Genetic toxicity studies with genistein. Food Chem. Toxicol. 2006, 44, 42-55.
130. Anderson, D., Dobrzynska, M. M., Basaran, N., Effect of various genotoxins and reproductive toxins in human lymphocytes and sperm in the Comet assay. Teratog. Carcinog. Mutagen. 1997, 17, 29-43.
131. Kulling, S. E., Rosenberg, B., Jacobs, E., Metzler, M., The phytoestrogens coumoestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. Arch. Toxicol. 1999, 73, 50-54.
132. Markovits, J., Linassier, C., Fosse, P., Couprie, J. et al., Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 1989, 49, 5111-5117.
133. Wisniewski, A. B., Klein, S. L., Lakshmanan, Y., Gearhart, J. P., Exposure to genistein during gestation and lactation demasculinizes the reproductive system in rats. J. Urol. 2003, 169, 1582-1586.
134. Hancock, K. D., Coleman, E. S., Tao, Y. X., Morrison, E. E. et al., Genistein decreases androgen biosynthesis in rat Leydig cells by interference with luteinizing hormone-dependent signaling. Toxicol. Lett. 2009, 184, 169-175.
135. Sherrill, J. D., Sparks, M., Dennis, J., Mansour, M. et al., Developmental exposures of male rats to soy isoflavones impact leydig cell differentiation. Biol. Reprod. 2010, 83, 488-501.
136. Jefferson, W. N., Padilla-Banks, E., Newbold, R. R., Studies of the effects of neonatal exposure to genistein on the developing female reproductive system. J. AOAC Int. 2006, 89, 1189-1196.
137. Kim, D. J., Seok, S. H., Baek, M. W., Lee, H. Y. et al., Developmental toxicity and brain aromatase induction by high genistein concentrations in zebrafish embryos. Toxicol. Mech. Methods 2009, 19, 251-256.
138. Sassi-Messai, S., Gibert, Y., Bernard, L., Nishio, S. et al., The phytoestrogen genistein affects zebrafish development through two different pathways. PloS ONE 2009, 4, e4935.
139. Hsieh, C. Y., Santell, R. C., Haslam, S. Z., Helferich, W. G., Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998, 58, 3833-3838.
140. Allred, C. D., Allred, K. F., Ju, Y. H., Virant, S. M., Helferich, W. G., Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001, 61, 5045-5050.
141. Allred, C. D., Allred, K. F., Ju, Y. H., Clausen, L. M. et al., Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 2004, 25, 211-218.
142. McMichael-Phillips, D. F., Harding, C., Morton, M., Roberts, S. A. et al., Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am. J Clin. Nutr. 1998, 68, 1431S-1435S.
143. Ju, Y. H., Doerge, D. R., Woodling, K. A., Hartman, J. A. et al., Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008, 29, 2162-2168.
144. Ju, Y. H., Doerge, D. R., Allred, K. F., Allred, C. D., Helferich, W. G., Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002, 62, 2474-2477.
145. Limer, J. L., Parkes, A. T., Speirs, V., Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int. J. Cancer 2006, 119, 515-521.
146. Liu, B., Edgerton, S., Yang, X., Kim, A. et al., Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005, 65, 879-886.
147. Klein, C. B., King, A. A., Genistein genotoxicity: critical considerations of in vitro exposure dose. Toxicol. Appl. Pharmacol. 2007, 224, 1-11.
148. Hercberg, S., Ezzedine, K., Guinot, C., Preziosi, P. et al., Antioxidant supplementation increases the risk of skin cancers in women but not in men. J. Nutr. 2007, 137, 2098-2105.
149. Lawson, K. A., Wright, M. E., Subar, A., Mouw, T. et al., Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J. Natl. Cancer Inst. 2007, 99, 754-764.
150. Miller, E. R., 3rd, Pastor-Barriuso, R., Dalal, D., Riemersma, R. A. et al., Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142, 37-46.
151. Lonn, E., Bosch, J., Yusuf, S., Sheridan, P. et al., Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. J. Am. Med. Assoc. 2005, 293, 1338-1347.
152. Poston, L., Briley, A. L., Seed, P. T., Kelly, F. J., Shennan, A. H., Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006, 367, 1145-1154.
153. Blot, W. J., Li, J. Y., Taylor, P. R., Guo, W. et al., Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 1993, 85, 1483-1492.
154. Hercberg, S., Galan, P., Preziosi, P., Bertrais, S. et al., The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch. Intern. Med. 2004, 164, 2335-2342.
155. Velicer, C. M., Ulrich, C. M., Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J. Clin. Oncol. 2008, 26, 665-673.
156. Lawenda, B. D., Kelly, K. M., Ladas, E. J., Sagar, S. M. et al., Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J. Natl. Cancer Inst. 2008, 100, 773-783.